Thyroid FNA advances
- Social posts promoted ultrasound‑guided thyroid biopsies emphasising precise lesion targeting and faster turnaround times. - One study post described ThyroProt using a 3‑protein signature plus BRAF V600E on 837 FNA samples for preoperative diagnosis. - The items together point to growing focus on technique and molecular triage to inform surgical decision‑making from limited FNA material ( ).
A thyroid fine-needle aspiration is a needle biopsy that pulls out a few cells, and ultrasound guidance helps place the needle inside the exact nodule being sampled. (thyroid.org) The American Thyroid Association says thyroid fine-needle aspiration is typically done in an office and usually under ultrasound guidance to improve needle placement. Mayo Clinic says some thyroid nodule clinics combine ultrasound evaluation and fine-needle aspiration in a single visit. (thyroid.org) (mayoclinic.org) The test is used because thyroid nodules are common and most are benign, while the overall malignancy risk in nodules selected for evaluation is often about 7% to 15%. Fine-needle aspiration is a central step in deciding which nodules can be watched and which need surgery. (ncbi.nlm.nih.gov) Pathologists usually report thyroid biopsy results with the Bethesda System, which sorts samples into categories from nondiagnostic to malignant. The American Thyroid Association says biopsy answers are clear in about 70% to 80% of nodules, while 20% to 30% land in an indeterminate zone. (thyroid.org 1) (thyroid.org 2) That indeterminate group is where newer add-on tests are aimed. In Bethesda III and IV nodules, the cells do not look clearly benign or clearly cancerous, so surgeons and patients often have to choose between repeat biopsy, molecular testing, surveillance, or diagnostic surgery. (thyroid.org 1) (thyroid.org 2) One recent study described a test called ThyroProt that combines measurements of three proteins with BRAF V600E mutation status, age, and sex from thyroid fine-needle aspiration material. The prospective, blinded, multicenter study developed and validated the classifier on 837 samples and reported results from a prospective test set of 322 samples. (ncbi.nlm.nih.gov) (sciencedirect.com) In that 322-sample prospective test set, the paper reported an area under the curve of 0.94 and overall accuracy of 90.7% for preoperative diagnosis. The same paper said the assay used targeted mass spectrometry, a lab method that measures selected proteins from very small amounts of material. (ncbi.nlm.nih.gov) BRAF V600E is already a familiar marker in thyroid testing because it is strongly linked to papillary thyroid carcinoma, the most common thyroid cancer type. A 2023 Scientific Reports paper said the latest Bethesda framework supports using genetic tests on indeterminate fine-needle aspiration samples, and it argued BRAF V600E testing is especially useful in Bethesda III or V nodules. (nature.com) (ncbi.nlm.nih.gov) Ultrasound technique still matters because even a strong molecular test depends on getting the right cells in the needle first. A Korean Society of Thyroid Radiology consensus statement said ultrasound-guided aspiration improves safety and accuracy, but nondiagnostic samples can still happen if the target is small, cystic, calcified, or hard to reach. (ncbi.nlm.nih.gov) The current shift is toward getting more decisions out of less tissue: one carefully targeted biopsy, one standardized cytology report, and one round of molecular triage before surgery. That does not remove the need for pathology or follow-up, but it can narrow the gray zone that has long defined thyroid fine-needle aspiration. (thyroid.org 1) (thyroid.org 2) (ncbi.nlm.nih.gov)
